Ionis Pharmaceuticals, Inc.

Good morning and welcome to IONIS Pharmaceutical's second quarter 2020 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walk, Vice President, Investor Relations, to lead off the call. Please begin.

Thank you, Ali. Before we begin, I encourage everyone to go to the investor section of the IONIS website to find the press release and related financial tables. including a reconciliation of the gap to non-gap financial measures that we will discuss today. We believe non-gap financial measures better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany our discussion today. With me on today's call are Brett Monia, Chief Executive Officer, Beth Haugen, Chief Financial Officer, and Richard Geary, Executive Vice President of Development. Additionally, joining us for Q&A are Oneza Katare, Chief Corporate Development and Commercial Officer, and Eric Swayze, Executive Vice President of Research. I'd like to draw your attention to slide three, which contains our forward-looking language statement. We will begin by making forward-looking – we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. With that, I'll turn the call over to Brett.

Thanks, Wade. Good morning, and thank you for joining us on today's call. The first half of this year was marked by numerous important achievements that position us well for success this year and in the future. This has been a remarkable year for many reasons, but in particular, for the tremendous strength and dedication demonstrated by the IONIS team. Our hard work has enabled us to remain on track to meet our key 2020 goals and achieve great success for years to come. And as we enter the second half of this year, I believe we are stronger than ever. Our phase three programs are on track with five studies in progress and two additional registration studies expected to start this year. Our mid and early stage medicines are making excellent progress with additional proof of concept data for several programs due later this year. We continue to grow and expand the scope of our clinical pipeline with new medicines advancing rapidly to treat many new diseases for which effective treatments are lacking. We also continue to grow the ionosome pipeline while in parallel developing our commercialization strategy in support of this pipeline. And we continue to advance and expand the reach of our technology at a record pace. Looking ahead, we remain on track to achieve our 2020 financial guidance, and we have the financial resources, the people, and the commitment to execute on our agenda. My vision for IONIS is to lead our industry in bringing transformative medicines to patients suffering with devastating diseases. Consistent with this goal, we anticipate and are on track to deliver 10 or more marketing applications for a range of devastating diseases through the end of 2025, which we expect to result in a number of new commercial medicines. Our recent accomplishments, including those made this year, position us well to achieve our goals. I'll now turn the call over to Beth to review our financial performance, followed by Richard, who will discuss our pipeline progress, and then I'll open the call up for questions after brief closing remarks. Beth?